Unknown

Dataset Information

0

An activin A/BMP2 chimera, AB204, displays bone-healing properties superior to those of BMP2.


ABSTRACT: Recombinant bone morphogenetic protein 2 (rhBMP2) has been used clinically to treat bone fractures in human patients. However, the high doses of rhBMP2 required for a therapeutic response can cause undesirable side effects. Here, we demonstrate that a novel Activin A/BMP2 (AB2) chimera, AB204, promotes osteogenesis and bone healing much more potently and effectively than rhBMP2. Remarkably, 1 month of AB204 treatment completely heals tibial and calvarial defects of critical size in mice at a concentration 10-fold lower than a dose of rhBMP2 that only partially heals the defect. We determine the structure of AB204 to 2.3 Å that reveals a distinct BMP2-like fold in which the Activin A sequence segments confer insensitivity to the BMP2 antagonist Noggin and an affinity for the Activin/BMP type II receptor ActRII that is 100-fold greater than that of BMP2. The structure also led to our identification of a single Activin A-derived amino acid residue, which, when mutated to the corresponding BMP2 residue, resulted in a significant increase in the affinity of AB204 for its type I receptor BMPRIa and a further enhancement in AB204's osteogenic potency. Together, these findings demonstrate that rationally designed AB2 chimeras can provide BMP2 substitutes with enhanced potency for treating non-union bone fractures.

SUBMITTER: Yoon BH 

PROVIDER: S-EPMC4276739 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

An activin A/BMP2 chimera, AB204, displays bone-healing properties superior to those of BMP2.

Yoon Byung-Hak BH   Esquivies Luis L   Ahn Chihoon C   Gray Peter C PC   Ye Sang-Kyu SK   Kwiatkowski Witek W   Choe Senyon S  

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20140901 9


Recombinant bone morphogenetic protein 2 (rhBMP2) has been used clinically to treat bone fractures in human patients. However, the high doses of rhBMP2 required for a therapeutic response can cause undesirable side effects. Here, we demonstrate that a novel Activin A/BMP2 (AB2) chimera, AB204, promotes osteogenesis and bone healing much more potently and effectively than rhBMP2. Remarkably, 1 month of AB204 treatment completely heals tibial and calvarial defects of critical size in mice at a con  ...[more]

Similar Datasets

| S-EPMC4643338 | biostudies-literature
| S-EPMC9834334 | biostudies-literature
| S-EPMC4122783 | biostudies-literature
| S-EPMC3149158 | biostudies-literature
| S-EPMC6525280 | biostudies-literature
| S-EPMC9508443 | biostudies-literature
| S-EPMC5282552 | biostudies-literature
| S-EPMC4280331 | biostudies-literature
| S-EPMC7858265 | biostudies-literature
| S-EPMC3572445 | biostudies-literature